Review



be0061, fully neutralizing mab recognizing cd8a  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Bio X Cell be0061, fully neutralizing mab recognizing cd8a
    Be0061, Fully Neutralizing Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/anti+cd8/pmc10561497-52-0-13
    Average 90 stars, based on 1 article reviews
    be0061, fully neutralizing mab recognizing cd8a - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies phospho-NF-kB p65 (Ser536) Cell Signaling Technology Cat# 3033S; RRID: AB_331284 NF-kB p65 Cell Signaling Technology Cat# 8242S; RRID: AB_10859369 b-Actin Cell Signaling Technology Cat# 3700S; RRID: AB_2242334 MYD88 Cell Signaling Technology Cat# 4283S; RRID: AB_10547882 LYN Cell Signaling Technology Cat# 2796S; RRID: AB_2138391 Lamin-B1 Santa Cruz Cat# sc-374015; RRID: AB_10947408 MYD88 Santa Cruz Cat# sc-74532; RRID: AB_1126429 TLR4 Santa Cruz Cat# sc-293072; AB_10611320 LYN Santa Cruz Cat# sc-7274; AB_627897 Normal mouse IgG Santa Cruz Cat# sc-2025; AB_737182 CD36 Abcam Cat# ab133625; RRID: AB_2716564 ZDHHC6 Abcam Cat# ab121423; RRID: AB_11129943 CD3 Abcam Cat# ab135372; RRID: AB_2884903 TLR4 CUSABIO Technology Cat# CSB-PA001434 InVivoPlus anti-mouse NK1.1 BioXcell Cat# BE0036; RRID: AB_1107737 InVivoMab anti-mouse CD8b BioXcell Cat# BE0223; RRID: AB_2687706 anti-mouse CD4 BioXcell Cat# BP0003-1; RRID: AB_1107636 InVivoPlus anti-mouse PD-L1 BioXcell Cat# BP0101; RRID: AB_10949073 InVivoPlus mouse IgG2a BioXcell Cat# BE0085; RRID: AB_1107771 InVivoPlus rat IgG1 BioXcell Cat# BE0088; RRID: AB_1107775 InVivoPlus rat IgG2b BioXcell Cat# BP0090; RRID: AB_1107780 Phospho-NFkB p65 (Ser529) Antibody, PE Invitrogen Cat# MA5-37165; RRID: AB_2897099 Arginase 1 Antibody, APC Invitrogen Cat# 17-3697-80; RRID: AB_2734834 Anti-human PD-L1-PE-Cy7 Invitrogen Cat# 25-5983-41; RRID: AB_1907369 Anti-mouse PD-1-BV785 BioLegend Cat# 135225; RRID: AB_2563680 Anti-mouse LAG-3-BV785 BioLegend Cat# 125219; RRID: AB_2566571 Anti-human PD-1-PE-Cy7 BioLegend Cat# 329917; RRID: AB_2159325 Anti-human CD8-FITC BioLegend Cat# 344704; RRID: AB_1877178 Anti-human CD14-BV421 BioLegend Cat# 301830; RRID: AB_10959324 Anti-mouse TIM3-PE eBioscience Cat# 12-5870-82; RRID: AB_465974 OVA257-264 (SIINFEKL) peptide bound to H-2K b Antibody, APC eBioscience Cat# 17-5743-80; RRID: AB_1311288 Anti-mouse CD36-APC eBioscience Cat# 17-0362-82; RRID: AB_2734967 Anti-mouse PD-L1-PE-Cy7 eBioscience Cat# 25-5982-82; RRID: AB_2573509 Anti-human TLR4-APC eBioscience Cat# 17-9917-41; RRID: AB_2016622 Anti-mouse CD107a-BV421 BD Biosciences Cat# 564347; RRID: AB_2738760 Anti-human CD33-BV421 BD Biosciences Cat# 562854; RRID: AB_2737405 Anti-human CD36-APC BD Biosciences Cat# 561822; RRID: AB_398480 Anti-human CD36-FITC BD Biosciences Cat# 555454; RRID: AB_2291112 Anti-human CD34-FITC BD Biosciences Cat# 555821; RRID: AB_396150 Anti-human CD34-APC BD Biosciences Cat# 561209; RRID: AB_10683161 Anti-human CD45-APC-Cy7 BD Biosciences Cat# 557833; RRID: AB_396891 Anti-human CD56-PE-Cy5 BD Biosciences Cat# 555517; RRID: AB_395907 (Continued on next page) Cell Reports Medicine 5, 101592, June 18, 2024 e1 Article ll OPEN ACCESS

    Article Title:
    Article Snippet: 17 CD8+ T-cells depletion 18 To deplete CD8+ T-cells, mice were given 200 μg anti-CD8 rat monoclonal antibody (clone 2.43, 19 BioXCell, cat# BP0061) or control antibody (clone LTF-2, BioXCell, cat# BP0090) i.p. every 3 20 days starting at 28 days of age.

    Article Title: MAP7D2 reduces CD8 cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer
    Article Snippet: 73 Characteristics Gender Pathological grade Female Male Stage: I + II Stage: IV + III Low MYH9 expression 6 13 14 5 High MYH9 expression 12 14 16 8 Low HMGB1 expression 8 13 15 6 High HMGB1 expression 11 13 17 7 Table S5 The oligonucleotide sequences, antibodies, and recombination protein 74 information 75 shRNA sequence human-shMAP7D2 sh1 GGAAGTTAATGGTGTGGATCA human-shMAP7D2 sh2 GCCAAGAAACTCCTCTCAACA mouse-shMAP7D2 sh1 GCCCAGTGAAGTCCAAGATCA mouse-shMAP7D2 sh2 GCCCTCTGAAGTCTAGCTACA mouse-siMYH9 si-1 GCTGCCAAGAAGTTGGTAT mouse-siMYH9 si-2 CCATGAGAATTATGGGCAT mouse-siMYH9 si-3 GCAGAACATCCAGGAACTT RT-PCR primer Genes Forward primer Reverse primer GAPDH GGAGCGAGATCCCTCCAAA AT GGCTGTTGTCATACTTCTCAT GG 7 MAP7D2 TCCCAGGGAAGATCGCAGA A TACTGCAGCCTGGCTCTTTT Antibody, recombination protein information Antibody name Company LOT NO. anti-CD8α Bioxcell BE0117 IgG2b Bioxcell BE0090 anti-PD-1 Bioxcell BE0146 IgG2α Bioxcell BE0089 anti-CD3 Biosciences #553057 anti-CD28 Biosciences #553294 CD3 Abcam ab16669 CD8 ZSGB-BIO ZA-0508 Anti-mouse CD3ε Biolegend 100320 anti-mouse CD8a Biolegend 100708 Zombie Violet Fixable Viability Biolegend 423114 MAP7D2 Abcam ab151140 MYH9 Proteintech P.11128-1-AP MYH9 Proteintech 60233-1-Ig HMGB1 Proteintech P.10829-1-AP HMGB1 Cell Signaling Technology 6893 β-Tubulin Cell Signaling Technology 86289 8 IL-2 SinoBiological #51061-MNAE HMGB1 protein SinoBiological #50913-M01H 76 Supplementary figures 77 78

    Article Title:
    Article Snippet: 30 Antibody-based T cell depletion 31 To eliminate circulating CD8+ T cells during chronic phase, a depleting anti-CD8β mAb (rat IgG1, 32 Lyt3.2, clone 53-5.8, cat # BX-BE0223 from BioXcell) was injected i.p. for 2 weeks, starting at 34 and 33 36 days post-infection (dpi) (200 μg per mouse), and then once at d41pi and once at d48pi (100 μg 34 per mouse), before euthanasia at d50pi.

    Article Title: Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-CTLA-4 (9D9) for in vivo use BioXcell BE0164; RRID:AB_10949609 Anti-PD-1 (RMP1-14) for in vivo use BioXcell BE0273; RRID:AB_2687796 Anti-CD137 (3H3) for in vivo use BioXcell BE0239; RRID:AB_2687721 Anti-CD4 (GK1.5) for in vivo use, depletion BioXcell BE0003-1; RRID:AB_1107636 Anti-CD8b (53-5.8) for in vivo use, depletion BioXcell BE0223; RRID:AB_2687706 RatIgG for in vivo use BioXcell BE0094; RRID:AB_1107795 Anti-CD3 (SP7) Abcam Ab16669; RRID:AB_443425 Anti-CD8 (D4W2Z) Cell Signaling Technology 98941; RRID:AB_2756376 Anti-Foxp3 (D6O8R) Cell Signaling Technology 12653; RRID:AB_2797979 Anti-CD4 (D7D2Z) Cell Signaling Technology 25229; RRID:AB_2798898 Anti-CD11b (6H12) Nous Biologicals NB110-89474; RRID:AB_1216361 Anti-KI-67 (rabbit polyclonal) Abcam Ab15580; RRID:AB_443209 Anti-cleaved Caspase-3 (Asp175) Cell Signaling Technology 9661; RRID:AB_2341188 Anti-Melanoma gp100 antibody [EP4863(2)] Abcam ab137078; RRID:AB_2732921 Anti-GFP (Green Fluorescent Protein) pAb (Polyclonal Antibody) Novus biologicals NB100-1770; RRID:AB_523903 Rabbit anti-Goat IgG (H + L) Secondary Antibody, Biotin Invitrogen 31732; RRID:AB_228393 PE Rabbit Anti- Active Caspase-3 BD Biosciences 51-68655X; RRID:AB_393957 Chemicals, peptides, and recombinant proteins Recombinant human IL-2 (Proleukin) Novartis CN70389 EGFP 118–126 (DTLVNRIEL) Genscript Han et al.21 Luciferase 264–272 (LMYRFEEEL) Genscript Limberis et al.20 Human gp100 petide KVPRNQDWL Genscript RP20344 c-Myc 229–238 (SSPQGSPEPL) Thermo-Scientific Helm et al.19 c-Myc 201–240 (DSSSPKSCASQDSSAFSPSSDSLL SSTESSPQGSPEPLVL) Thermo-Scientific Helm et al.19 OVA 257–264 (SIINFEKL) Invitrogen Vac-sin D-luciferine Xenogen XR-1001 DAPI Akoya-Biosciences FP1490 Faramount aqueous mounting medium Dako S3025 Citrate unmasking solution Cell Signaling Technology 14746 (Continued on next page) Cell Reports Medicine 4, 101009, April 18, 2023 e1

    Article Title: Supplemental Information MAP7D2 reduces CD8 cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer
    Article Snippet: 73 Characteristics Gender Pathological grade Female Male Stage: I + II Stage: IV + III Low MYH9 expression 6 13 14 5 High MYH9 expression 12 14 16 8 Low HMGB1 expression 8 13 15 6 High HMGB1 expression 11 13 17 7 Table S5 The oligonucleotide sequences, antibodies, and recombination protein 74 information 75 shRNA sequence human-shMAP7D2 sh1 GGAAGTTAATGGTGTGGATCA human-shMAP7D2 sh2 GCCAAGAAACTCCTCTCAACA mouse-shMAP7D2 sh1 GCCCAGTGAAGTCCAAGATCA mouse-shMAP7D2 sh2 GCCCTCTGAAGTCTAGCTACA mouse-siMYH9 si-1 GCTGCCAAGAAGTTGGTAT mouse-siMYH9 si-2 CCATGAGAATTATGGGCAT mouse-siMYH9 si-3 GCAGAACATCCAGGAACTT RT-PCR primer Genes Forward primer Reverse primer GAPDH GGAGCGAGATCCCTCCAAA AT GGCTGTTGTCATACTTCTCAT GG MAP7D2 TCCCAGGGAAGATCGCAGA A TACTGCAGCCTGGCTCTTTT Antibody, recombination protein information Antibody name Company LOT NO. anti-CD8α Bioxcell BE0117 IgG2b Bioxcell BE0090 anti-PD-1 Bioxcell BE0146 IgG2α Bioxcell BE0089 anti-CD3 Biosciences #553057 anti-CD28 Biosciences #553294 CD3 Abcam ab16669 CD8 ZSGB-BIO ZA-0508 Anti-mouse CD3ε Biolegend 100320 anti-mouse CD8a Biolegend 100708 Zombie Violet Fixable Viability Biolegend 423114 MAP7D2 Abcam ab151140 MYH9 Proteintech P.11128-1-AP MYH9 Proteintech 60233-1-Ig HMGB1 Proteintech P.10829-1-AP HMGB1 Cell Signaling Technology 6893 β-Tubulin Cell Signaling Technology 86289 IL-2 SinoBiological #51061-MNAE HMGB1 protein SinoBiological #50913-M01H 76 Supplementary figures 77 78 Figure S1 79 The clinical relevance of MAP7D2 and its expression in paired CRC and adjacent 80 normal tissues. (A) Representative IHC staining images of MAP7D2 from 10 paired 81 CRC and adjacent normal tissues.

    Injection:

    Article Title: Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells.
    Article Snippet: .. Two days before tumor inoculation, 200 μg of CD8 depletion antibody (2.43, Bio X Cell) or rat IgG (2A3, Bio X Cell) were intraperitoneally injected into the indicated group, respectively. ..



    Similar Products

    94
    Bio X Cell mab recognizing cd8a
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/Anti-Human+CD8+Cd8a+Monoclonal+Antibody+mFluor540+Conjugated%2C+Flow+Validated/pm37814340-61-4-13
    Average 94 stars, based on 1 article reviews
    mab recognizing cd8a - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Bio X Cell be0061, fully neutralizing mab recognizing cd8a
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Be0061, Fully Neutralizing Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/anti+cd8/pmc10561497-52-0-13
    Average 90 stars, based on 1 article reviews
    be0061, fully neutralizing mab recognizing cd8a - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher a different clone of mab recognizing cd8a (ct-cd8a; igg2a)
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    A Different Clone Of Mab Recognizing Cd8a (Ct Cd8a; Igg2a), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/10__1182_slash_blood__v96__5__1865-53-31-39
    Average 90 stars, based on 1 article reviews
    a different clone of mab recognizing cd8a (ct-cd8a; igg2a) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.

    doi: 10.1186/s13046-023-02831-w

    Figure Lengend Snippet: Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

    Article Snippet: BE0061, a fully neutralizing mAb recognizing CD8a, and control IgG were obtained from Bioxcell.

    Techniques: Immunostaining, Flow Cytometry